Ramy Riad: Advancing Plasma-Derived Therapies Through Partnership
Ramy Riad, President of Plasma-Derived Therapies Business Unit at Takeda, shared a post on LinkedIn:
“Wrapping up a productive first day at IPPC 2026, hosted by Plasma Protein Therapeutics Association (PPTA), with a real sense of momentum.
This year’s theme — ‘Resilience, Reach and Responsibility’ — perfectly captures the leadership imperative facing our industry.
No single organization can sustain the plasma ecosystem alone.
It requires long‑term partnerships and shared responsibility across the value chain.
Today’s conversations reinforced how essential collaboration is to protect access for the patients who depend on plasma-derived therapies.
Looking forward to the sessions ahead and to connecting with fellow leaders shaping the future of plasma.”
Stay updated with Hemostasis Today.
-
Jun 29, 2026, 01:11Gerrit M. Grosse: Mapping the Landscape of Biomarkers in Post-Stroke Cognitive Impairment
-
Jun 29, 2026, 01:07Katerina Pavenski: Key Insights on Patient Blood Management at ISBT 2026
-
Jun 28, 2026, 19:05Jack Shuang Hou: Novo Nordisk to Present New Haemophilia Data on Investigational Denecimig at ISTH 2026
-
Jun 28, 2026, 19:05Pinar Demirtepe: Not All “Blood Thinners” Are the Same
-
Jun 28, 2026, 19:05Andrea Cesari: Comparing Catheter-Based Reperfusion Strategies for Intermediate-High-Risk PE
-
Jun 28, 2026, 19:02Nassim Emteir: Interpreting TSAT with Ferritin to Guide Iron Deficiency Diagnosis and Treatment
-
Jun 28, 2026, 19:00Andrew Jackson: Predicting PICC-Related Venous Thrombosis in Patients Undergoing Radiotherapy
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations